9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
The DOI matches its Crossref record; 90 of the 94 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the latest American Diabetes Association (ADA) [62], Italian Society of Diabetology (SID) [63] and KDIGO guidelines [64] differentiate the pharmacological approach to T2DM not just based on the target glycaemic values but also taking into account the indicators of high-risk or established atherosclerotic cardiovascular disease, CKD and heart failure.”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [62]
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“temshasbeensupported in the literature in adolescents and adults with type 1 diabetes (16,17), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults with type 1 diabetes (…”
BackgroundHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Research works printed but not linked: 3
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Chiang, 2014, Type 1 diabetes through the life span: a position statement of the American Diabetes Association
- Lipska, 2018, Association of initiation of basal insulin analogs vs neutral protamine hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes, 53
Cited by
Items 401–500 of 975
Diabetes mellitus and heart failure: an update on pathophysiology and therapy
Potere, N., BUONO, M. G. D., Vecchié, A., Porreca, E., ABBATE, A., DENTALI, F., & Bonaventura, A. (2022) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.22.05967-1 · Cited by 11
Dagogo-Jack, S. E., Cannon, C. P., Cherney, D. Z. I., Cosentino, F., Liu, J., Pong, A., Gantz, I., Frederich, R. C., Mancuso, J. P., & Pratley, R. E. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14691 · Cited by 10
Oh, S., Purja, S., Shin, H., Kim, M., & Kim, E. Y. (2022) · Diabetes and Vascular Disease Research · doi:10.1177/14791641221106866 · Cited by 14
Zhou, J., Chen, S., Cheng, J., Zhu, J., Lou, Y., Bao, Y., & Jia, W. (2022) · 中国科学通报:英文版 · doi:10.1016/j.scib.2022.08.002 · Cited by 13
The societal impact of early intensified treatment in patients with type 2 diabetes mellitus
Tsotra, F., Kappel, M., Peristeris, P., Bader, G., Levi, E., Lister, N., Malhotra, A., & Ostwald, D. A. (2022) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2022-0110 · Cited by 11
Metformin therapy in pediatric type 2 diabetes mellitus and its comorbidities: A review
Alfaraidi, H., & Samaan, M. C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1072879 · Cited by 13
El‐Khateeb, E., Elberri, E. I., Mosalam, E. M., Nooh, M. Z., Abdelsattar, S., Alghamdi, A. M., Alrubia, S., & Abdallah, M. S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1153653 · Cited by 12
“If the HbA1c target is not achieved or maintained after 3–6 months of metformin monotherapy at the maximum tolerated dose (2000 mg), treatment modification with the addition of a second oral antihyperglycemic agent or the initiation of insulin is recommended (Association, 2020).”
BackgroundLaursen, H. V. B., Jørgensen, E. P., Vestergaard, P., & Ehlers, L. H. (2023) · PharmacoEconomics · doi:10.1007/s40273-023-01268-5 · Cited by 14
Impaired metabolic effects of metformin in men with early-onset androgenic alopecia
Krysiak, R. G., Kowalcze, K. E., & Okopień, B. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00347-8 · Cited by 12
Casula, M., Catapano, A. L., & Magni, P. (2022) · Nutrients · doi:10.3390/nu14030606 · Cited by 17
Exenatide Once Weekly for Management of Type 2 Diabetes: A Review
Inaishi, J., & Saisho, Y. (2022) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s288846 · Cited by 14
Hereditary renal glycosuria, diabetes and responses to SGLT2 inhibitor
Ren, Q., Gong, S., Han, X., & Ji, L. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13254 · Cited by 11
Yun, J., Han, K., & Ko, S. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13786 · Cited by 11
Huang, E. S., Liu, J. Y., Lipska, K. J., Grant, R. W., Laiteerapong, N., Moffet, H. H., Schumm, L. P., & Karter, A. J. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18310 · Cited by 11
Di Molfetta, S., Bosi, E., Ceriello, A., Cucinotta, D., Tiengo, A., Scavini, M., Piccolo, C., Bonizzoni, E., Acmet, E., & Giorgino, F. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109070 · Cited by 10
Yun, J., Han, K., Park, Y., Han, E., Lee, Y., & Ko, S. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13818 · Cited by 16
Badi, S., Suliman, S. Z., Almahdi, R., Aldomah, M. A., Marzouq, M. E., Ibrahim, E. E. M., Ahmed, M., Ahmed, M. H., Elkheir, H. K., & Ibrahim, M. I. M. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14010074 · Cited by 20
“The American Diabetes Association encourages a reassessment of therapeutic regimen and drug intake on a constant basis every six months at maximum to carry out drug modifications as needed to achieve therapeutic goals [6].”
BackgroundLugo-Fabres, P. H., Otero-Sastre, L. M., Bernáldez-Sarabia, J., Camacho-Villegas, T. A., Sánchez-Campos, N., Serrano‐Bello, J., Medina, L. A., Muñiz‐Hernández, S., de la Cruz, L., Arenas, I., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9080936 · Cited by 10
Home, P. D., Mehta, R., Hafidh, K., Gurova, O. Y., Alvarez, A., Serafini, P. R., & Pourrahmat, M. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14518 · Cited by 9
Metformin-associated lactic acidosis and acute kidney injury in the era of COVID-19
Vordoni, A., Theofilis, P., Vlachopanos, G., Koukoulaki, M., & Kalaitzidis, R. (2021) · Frontiers in Bioscience-Scholar · doi:10.52586/s563 · Cited by 10
Imrisek, S. D., Lee, M., Goldner, D., Nagra, H., Lavaysse, L. M., Hoy‐Rosas, J., Dachis, J., & Sears, L. E. (2022) · JMIR Diabetes · doi:10.2196/34624 · Cited by 12
One hundred years of insulin: Is it time for smart?
Gilor, C., & Fleeman, L. M. (2022) · Journal of Small Animal Practice · doi:10.1111/jsap.13507 · Cited by 13
Seo, D. H., Suh, Y. J., Cho, Y., Ahn, S. H., Seo, S., Hong, S., Lee, Y., Choi, Y. J., Lee, E. J., & Kim, S. H. (2022) · Yonsei Medical Journal · doi:10.3349/ymj.2022.63.9.825 · Cited by 10
Vázquez-Agra, N., Cruces‐Sande, A., Méndez‐Álvarez, E., Soto‐Otero, R., Cinza‐Sanjurjo, S., Lopez-Paz, J.-E., Pose‐Reino, A., & Ameijeiras, Á. H. (2022) · Antioxidants · doi:10.3390/antiox11122430 · Cited by 12
Scheen, A. J. (2022) · Annals of Translational Medicine · doi:10.21037/atm-2022-54 · Cited by 9
GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice
Romera, I., Santos, M. R., Artola, S., Fernández, C. S., & Conget, I. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02442-z · Cited by 12
Scutca, A.-C., Nicoară, D.-M., Mang, N., Jugănaru, I., Brad, G.-F., & Mărginean, O. (2023) · Biomedicines · doi:10.3390/biomedicines11112976 · Cited by 13
Heo, E. Y., Kim, E., Jang, E. J., & Lee, C. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01667-4 · Cited by 12
Treatment of type 2 diabetes in children: what are the specific considerations?
Grøndahl, M. F. G., Johannesen, J., Kristensen, K., & Knop, F. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1954160 · Cited by 13
Wolver, S. E., Fadel, K., Fieger, E., Aburish, Z., O'Rourke, B., Chandler, T.-M., Shimotani, D., Clingempeel, N. L., Jain, S., Jain, A., et al. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.690855 · Cited by 15
Physiologic Insulin Resensitization as a Treatment Modality for Insulin Resistance Pathophysiology
Greenway, F. L., Loveridge, B., Grimes, R. M., Tucker, T. R., Alexander, M., Hepford, S. A., Fontenot, J., Nobles‐James, C., Wilson, C., Starr, A. M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031884 · Cited by 11
Ishii, H. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13799 · Cited by 12
Schnaars, Y., Gaikwad, S., Gottwald‐Hostalek, U., Klingberg, U., Vadla, H. K. C., & Prathap, V. R. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01269-1 · Cited by 13
Takeuchi, M., Ogura, M., Inagaki, N., & Kawakami, K. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002636 · Cited by 12
Eghbali‐Zarch, M., Tavakkoli-Moghaddam, R. R., Esfahanian, F., & Masoud, S. (2022) · Medical & Biological Engineering & Computing · doi:10.1007/s11517-022-02602-3 · Cited by 11
The first successful desensitization protocol in exenatide allergy: a case report
Yeğit, O. O., Sarıbeyliler, G., Karadağ, P., Demir, S., Gül, N., Ünal, D., & Gelincik, A. A. (2023) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-023-00761-y · Cited by 12
Lavalle-Cobo, A., Masson, W., Lobo, M., Masson, G., & Molinero, G. (2021) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00479-1 · Cited by 9
The effect of Dulaglutide on glycemic and weight control in patients with type 2 diabetes
Ruda, A. I., Ciobanu, D. M., Inceu, G., Rusu, A., & Román, G. (2022) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2425 · Cited by 9
Preda, V. A., Khoo, S. S.-Y., Preda, T. C., & Lord, R. V. (2023) · BJS Open · doi:10.1093/bjsopen/zrac169 · Cited by 9
Longitudinal Studies of Wearables in Patients with Diabetes: Key Issues and Solutions
Alhaddad, A. Y., Aly, H., Gad, H., Elgassim, E., Mohammed, I., Baagar, K. A. M., Al-Ali, A. K., Sadasivuni, K. K., Cabibihan, J., & Malik, R. A. (2023) · Sensors · doi:10.3390/s23115003 · Cited by 16
“Patients with diabetes need to maintain optimal blood glucose levels and avoid hypoglycemia by monitoring their blood sugar, regulating their calorie intake, and adhering to treatment strategies [12–15].”
Shand, J. A. D., Young, S., Verster, F., & Peters, C. N. (2023) · BMJ Nutrition Prevention & Health · doi:10.1136/bmjnph-2023-000733 · Cited by 10
The role of protein O-GlcNAcylation in diabetic cardiomyopathy
Chatham, J. C., & Wende, A. R. (2024) · Biochemical Society Transactions · doi:10.1042/bst20240262 · Cited by 9
Rizvi, A. A., Linhart, A., Vrablı́k, M., Liberopoulos, E. N., & Rizzo, M. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2043848 · Cited by 9
Multivariate Models of Blood Glucose Prediction in Type1 Diabetes: A Survey of the State-of-the-art
Kumar, S., Arora, S., & Kumar, P. (2022) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023666220603092433 · Cited by 13
Aberer, F., Pieber, T. R., Eckstein, M. L., Sourij, H., & Moser, O. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061180 · Cited by 12
Sacre, J. W., Magliano, D. J., & Shaw, J. E. (2022) · Diabetes Care · doi:10.2337/dc21-1929 · Cited by 9
Soares, A. R., Coelho, M., Tracey, M., Carvalho, D. M., & Silva‐Nunes, J. (2023) · Diabetes Therapy · doi:10.1007/s13300-022-01358-1 · Cited by 11
An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review
Dagli, N., Kumar, S., Ahmad, R., Narwaria, M., & Haque, M. (2023) · Cureus · doi:10.7759/cureus.46510 · Cited by 16
An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus
Novodvorský, P., & Haluzík, M. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1978974 · Cited by 13
Khunti, K., Heerspink, H. J. L., Lam, C. S. P., Nicolucci, A., Ramirez, L., Surmont, F., Fenici, P., & Kosiborod, M. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108077 · Cited by 10
Guja, C., Giorgino, F., Blonde, L., Ali, A., Prázný, M., Meier, J. J., Souhami, E., LUBWAMA, R. N., Ji, C. F., & Rosenstock, J. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01180-1 · Cited by 9
Schechter, M., Fischer, M., & Mosenzon, O. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14675 · Cited by 8
Metformin-associated Lactic Acidosis with Hypoglycemia during the COVID-19 Pandemic
Takayama, K., Obata, Y., Maruo, Y., Yamaguchi, H., Kosugi, M., Irie, Y., Hazama, Y., & Yasuda, T. (2022) · Internal Medicine · doi:10.2169/internalmedicine.9179-21 · Cited by 11
Jin, Y., So, H., Cerin, E., Barnett, A. H., Mubarik, S., Hezam, K., Feng, X., Wang, Z., Huang, J., Zhong, C., et al. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1035439 · Cited by 12
Wancewicz, B., Zhu, Y., Fenske, R. J., Weeks, A. M., Wenger, K., Pabich, S., Daniels, M., Punt, M., Nall, R., Peter, D. C., et al. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001493 · Cited by 10
Deng, Y., Polley, E. C., Wallach, J. D., Herrin, J. S., Ross, J. S., & McCoy, R. G. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000419 · Cited by 10
Newer drug treatments for type 2 diabetes
Guo, J. S., & Smith, S. M. (2021) · BMJ · doi:10.1136/bmj.n1171 · Cited by 10
Gregg, E. W., & Moin, T. (2021) · JAMA · doi:10.1001/jama.2021.12559 · Cited by 9
Li, Y., Tang, H., Guo, Y. M., Shao, H., Kimmel, S. E., Bian, J., Schatz, D., & Guo, J. S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1379251 · Cited by 10
El-Demerdash, A. A., Darwish, S. F., El-Derany, M. O., & El‐Demerdash, E. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01750-w · Cited by 9
Chen, C., Peng, H., Li, M., Lu, X., Huang, M., Zeng, Y., & Dong, G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.664533 · Cited by 10
Romera, I., Artime, E., Ihle, K., Díaz‐Cerezo, S., Santos, M. R., Prado, A. D., Cuenca, A. M. C., & Conget, I. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02196-0 · Cited by 7
Zaghloul, N., Awaisu, A., Mahfouz, A., Alyafei, S., & Elewa, H. F. (2022) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-022-01464-x · Cited by 9
Dimakos, J., Cui, Y. J., Platt, R. W., Renoux, C., Filion, K. B., & Douros, A. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2975 · Cited by 10
Brockmeyer, M., Parco, C., Vargas, K. G., Westenfeld, R., Jung, C., Kelm, M., Roden, M., Akbulut, C., Schlesinger, S., Wolff, G., et al. (2024) · Journal of Nephrology · doi:10.1007/s40620-023-01858-8 · Cited by 9
“In subjects with T2DM and mild or moderate CKD, treatment with GLP-1 receptor agonists or SGLT2 inhibitors should be initiated, if therapy additional to metformin is required [58].”
BackgroundAlenzi, S., Alzahrani, A., Aljaloud, A., Alanazi, K., & Alarfaj, S. J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1395651 · Cited by 10
Popovic, D. S., Rizzo, M., Stokić, E., & Παπάνας, Ν. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01065-3 · Cited by 11
Krysiak, R. G., Kowalcze, K. E., & Okopień, B. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13528 · Cited by 8
Kawaguchi, Y., Miyamoto, S., Hajika, Y., Ashida, N., Masumoto, K., Sawa, J., Hamazaki, K., & Kumeda, Y. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13677 · Cited by 8
Majithia, A. R., Erani, D. M., Kusiak, C. M., Layne, J. E., Lee, A. A., Colangelo, F. R., Romanelli, R. J., Robertson, S., Brown, S. M., Dixon, R. F., et al. (2022) · JMIR Formative Research · doi:10.2196/31629 · Cited by 9
Lee, M., Lee, W., Kim, J. H., & Lee, B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14679 · Cited by 14
Rising cost of insulin: A deterrent to compliance in patients with diabetes mellitus
Zargar, A. H., Kalra, S., M., P. K. K., Murthy, S., Negalur, V. B., Rajput, R., Rastogi, A., Saboo, B., Sharma, S. K., Sahay, R. K., et al. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102528 · Cited by 13
Serum vitamin B12 levels and glycemic fluctuation in patients with type 2 diabetes mellitus
Li, W., Zhao, J., Zhu, L., & Peng, Y. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221102800 · Cited by 11
Shao, H., Alsaleh, A. J. O., DEX, T. A., Lew, E., & Fonseca, V. A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01300-5 · Cited by 10
Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults
Dadwani, R. S., Wan, W., Skandari, M. R., & Huang, E. S. (2023) · MDM Policy & Practice · doi:10.1177/23814683231187566 · Cited by 8
Esteghamati, A., Zamanzadeh, M., Malek, M., Khaledi, M., MONAVVARI, A., Najafi, L., Banazadeh, Z., Malboosbaf, R., Aghili, R., Mahdikhah, S., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01462-w · Cited by 9
Feng, W., Chen, W., Jiang, S., Du, L., & Zhu, D. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14392 · Cited by 9
Vargas‐Uricoechea, H., Núñez, J. L. B., Guzmán, J. R., Silva‐Gomez, L., Beltran, S., & Sañudo‐Maury, M. E. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14868 · Cited by 8
Variations in Use of Diabetes Drugs With Cardiovascular Benefits Among Medicaid Patients
Zhai, M. Z., Avorn, J., Liu, J., & Kesselheim, A. S. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.40117 · Cited by 7
Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes
Marquis‐Gravel, G., & Tardif, J. (2021) · Diabetes Care · doi:10.2337/dci20-0076 · Cited by 7
Suastika, K., Eliana, F., Kshanti, I. A., Mardianto, M., Mudjarnako, S. W., Natalia, N., Seno, H. N. H., Sibarani, R. P., Soewondo, P., Soelistijo, S. A., et al. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s367153 · Cited by 7
CommonABCB1SNP, C3435T could affect systemic exposure of dapagliflozin in healthy subject
Hwang, J. G., Jeong, S. I., Kim, Y. K., Lee, Y., Ji, S. C., Lee, S., & Park, M. K. (2022) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2022.30.e23 · Cited by 7
Prediction of complications in health economic models of type 2 diabetes: a review of methods used
Li, X., Li, F., Wang, J., van Giessen, A., & Feenstra, T. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02045-8 · Cited by 8
Insulin: Know what your immunoassay detects. Evaluation of two new immunoassays
Violin, A., Enard, E., Blin, J., Paillusson, D., Collin, A., Guénet, D., Raverot, V., Bach‐Ngohou, K., & Masson, D. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117516 · Cited by 8
Tesfaye, H., Wang, K. M., Zabotka, L. E., Wexler, D. J., Schmedt, N., Koeneman, L., SEMAN, L. J., Paik, J. M., & Patorno, E. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-08793-9 · Cited by 10
Attia, M. S., Ayman, F., Attia, M. S., Yahya, G., Zahra, M. H., Khalil, M. M. I., & Diab, A. A. A. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i8.1778 · Cited by 9
Maruyama‐Sakurai, K., Tachimori, H., Saito, E., Kohsaka, S., Segawa, Y., Miyata, H., & Igarashi, A. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15832 · Cited by 7
Tanaka, A., Shimabukuro, M., Teragawa, H., Okada, Y., Takamura, T., Taguchi, I., Toyoda, S., Tomiyama, H., Ueda, S., Higashi, Y., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01352-0 · Cited by 10
Primary Prevention of CVD with Aspirin: Benefits vs Risks
Weisman (2021) · The Journal of Family Practice · doi:10.12788/jfp.0222 · Cited by 9
Frías, J. P., Bonora, E., Cox, D. A., Bethel, M. A., Kwan, A. Y. M., Raha, S., & Malik, R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14533 · Cited by 8
The role of the nurse in the Obesity Clinic: a practical guideline
Barrea, L., FRAMONDI, L., MATTEO, R. D., Verde, L., Vetrani, C., GRAZIADIO, C., PUGLIESE, G., LAUDISIO, D., Vitale, G., IANNICELLI, A., et al. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.21.04540-7 · Cited by 11
Rosenberg, Y., Görtz, H., Rother, U., Uhl, C., Stavroulakis, K., Pfeiffer, M., Pfeiffer-Krahl, M., & Behrendt, C. (2021) · Gefässchirurgie · doi:10.1007/s00772-021-00855-0 · Cited by 7
A Retrospective Analysis of Hematologic Parameters in Patients with Early Diabetic Kidney Disease
Chen, X., Wang, Q., & Li, C. (2022) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296221083681 · Cited by 7
Liu, H., Hou, H., Yang, M., Hou, Y., Shan, Z., & Cao, Y. (2022) · BMC Family Practice · doi:10.1186/s12875-022-01663-5 · Cited by 7
Bailey, T. S., Gill, J., Merwyn Jones, S., Shenoy, L., Nicholls, C. J., & Westerbacka, J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14739 · Cited by 7
Gasser, B. A., Kurz, J., Buerki, S., & Mohaupt, M. G. (2022) · Life · doi:10.3390/life12070998 · Cited by 8
Safety of sodium–glucose c otransporter 2 inhibitors in Asian type 2 diabetes populations
Davidson, J. A., Sukor, N., Hew, F., Mohamed, M., & Hussein, Z. B. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13915 · Cited by 9
Al-Jedai, A. H., Almudaiheem, H., Alissa, D. A., Al-Enazy, H. S., Korayem, G. B., Alghamdi, A., & Alghamdi, S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273836 · Cited by 8
Sinha, A., Ning, H., Cameron, N. A., Bancks, M. P., Carnethon, M. R., Allen, N. B., Wilkins, J. T., Lloyd‐Jones, D. M., & Khan, S. S. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.10.426 · Cited by 10
Burnette, S., Poehlein, E., Lee, H., Force, J. M., Westbrook, K. E., & Moore, H. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06798-8 · Cited by 8
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-12-04
- Volume
- 44
- Issue
- Supplement_1
- Pages
- S111-S124
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4254445254
- Cited by
- 972
- References
- 94
- Citations by year
- 2026: 29 · 2025: 55 · 2024: 86 · 2023: 148 · 2022: 334 · 2021: 318 · 2020: 1
- FWCI
- 30.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- pharmacotherapy, diabetes management, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.